A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.
Advanced Solid Tumors
BIOLOGICAL: IMC-A12|BIOLOGICAL: IMC-A12|BIOLOGICAL: IMC-A12|BIOLOGICAL: IMC-A12|BIOLOGICAL: IMC-A12
Number of participants with Adverse Events (AEs), 8 weeks|Maximum Tolerated Dose, 8 weeks
Maximum concentration (Cmax), cohorts 1, 2, 3, 4, and 5, 8 weeks|Minimum concentration (Cmin), cohorts 1, 2, 3, 4, and 5, 8 weeks|Area under concentration (AUC), cohorts 1, 2, 3, 4, and 5, 8 weeks|Half-life (t 1/2), cohorts 1, 2, 3, 4, and 5, 8 weeks|Clearance (Cl) rate drug is completely removed, cohorts 1, 2, 3, 4, and 5, 8 weeks|Volume of distribution (Vss) at steady state, cohorts 1, 2, 3, 4, and 5, 8 weeks|Serum Anti-IMC-A12 Antibody Assessment (immunogenicity), 8 weeks|Change in tumor size from Baseline Measurement, 8 weeks
The purpose of this study is to establish the safety profile and maximum tolerated dose (MTD) of the anti-IGF-IR monoclonal antibody IMC-A12 administered every other week in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.